UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 18.

Avila, E K; Chamberlain, M; Schiff, D; Reijneveld, J C; Armstrong, T S; Ruda, R; Wen, P Y; Weller, M; Koekkoek, J A F; Mittal, S; Arakawa, Y; Choucair, A; Gonzalez-Martinez, J; MacDonald, D R; Nishikawa, R; Shah, A; Vecht, C J; Warren, P; van den Bent, M J; DeAngelis, L M (2017). Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. Neuro-Oncology, 19(1):12-21.

Esposito, G; Burgunder, J M; Dunlop, J; Gorwood, P; Inamdar, A; Pfister, S M; Pochet, R; van den Bent, M J; Van Hoylandt, N; Weller, M; Westphal, M; Wick, W; Nutt, D (2016). Gene-Tailored Treatments for Brain Disorders: Challenges and Opportunities. Public Health Genomics, 19(3):170-177.

Ellingson, B M; Bendszus, M; Boxerman, J; Barboriak, D; Erickson, B J; Smits, M; Nelson, S J; Gerstner, E; Alexander, B; Goldmacher, G; Wick, W; Vogelbaum, M; Weller, M; Galanis, E; Kalpathy-Cramer, J; Shankar, L; Jacobs, P; Pope, W B; Yang, D; Chung, C; Knopp, M V; Cha, S; van den Bent, M J; Chang, S; Yung, W K; Cloughesy, T F; Wen, P Y; Gilbert, M R (2015). Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro-Oncology, 17(9):1188-1198.

Kurscheid, S; Bady, P; Sciuscio, D; Samarzija, I; Shay, T; Vassallo, I; Criekinge, W V; Daniel, R T; van den Bent, M J; Marosi, C; Weller, M; Mason, W P; Domany, E; Stupp, R; Delorenzi, M; Hegi, M E (2015). Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma. Genome Biology, 16(1):16.

Kros, J M; Huizer, K; Hernandez-Lain, A; Marucci, G; Michotte, A; Pollo, B; Rushing, E J; Ribalta, T; French, P; Jamine, D; Bekka, N; Lacombe, D; van den Bent, M J; Gorlia, T (2015). Evidence-based diagnostic algorithm for glioma: analysis of the results of pathology panel review and molecular parameters of EORTC 26951 and 26882 trials. Journal of Clinical Oncology, 33(17):1943-1950.

Stupp, R; Hegi, M E; Gorlia, T; et al; Kim, C Y; Nabors, L B; Reardon, D A; van den Bent, M J; Hicking, C; Markivskyy, A; Picard, M; Weller, M (2014). Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, 15(10):1100-1108.

Bady, P; Sciuscio, D; Diserens, A C; Bloch, J; van den Bent, M J; Marosi, C; Dietrich, P Y; Weller, M; Mariani, L; Heppner, F L; Macdonald, D R; Lacombe, D; Stupp, R; Delorenzi, M; Hegi, M E (2013). Erratum to: MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathologica, 126(1):159.

Laperriere, N; Weller, M; Stupp, R; Perry, J R; Brandes, A A; Wick, W; van den Bent, M J (2013). Optimal management of elderly patients with glioblastoma. Cancer Treatment Reviews, 39(4):350-357.

Bady, P; Sciuscio, D; Diserens, A C; Bloch, J; van den Bent, M J; Marosi, C; Dietrich, P Y; Weller, M; Mariani, L; Heppner, F L; McDonald, D R; Lacombe, D; Stupp, R; Delorenzi, M; Hegi, M E (2012). MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathologica, 124(4):547-560.

Galanis, E; Wu, W; Cloughesy, T; Lamborn, K; Mann, B; Wen, P Y; Reardon, D A; Wick, W; Macdonald, D; Armstrong, T S; Weller, M; Vogelbaum, M; Colman, H; Sargent, D J; van den Bent, M J; Gilbert, M; Chang, S (2012). Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncology, 13(5):e196-e204.

Hegi, M E; Janzer, R C; Lambiv, W L; Gorlia, T; Kouwenhoven, M C M; Hartmann, C; von Deimling, A; Martinet, D; Besuchet Schmutz, N; Diserens, A C; Hamou, M F; Bady, P; Weller, M; van den Bent, M J; Mason, W P; Mirimanoff, R O; Stupp, R; Mokhtari, K; Wesseling, P (2012). Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathologica, 123(6):841-852.

Weller, M; Gorlia, T; Cairncross, J G; van den Bent, M J; Mason, W; Belanger, K; Brandes, A A; Bogdahn, U; Macdonald, D R; Forsyth, P; Rossetti, A O; Lacombe, D; Mirimanoff, R-O; Vecht, C J; Stupp, R (2011). Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology, 77(12):1156-1164.

Weller, M; Stupp, R; Reifenberger, G; Brandes, A A; van den Bent, M J; Wick, W; Hegi, M E (2010). MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nature Reviews. Neurology, 6(1):39-51.

Tabatabai, G; Stupp, R; van den Bent, M J; Hegi, M E; Tonn, J C; Wick, W; Weller, M (2010). Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathologica, 120(5):585-592.

Grisariu, S; Avni, B; Batchelor, T T; van den Bent, M J; Bokstein, F; Schiff, D; Kuittinen, O; Chamberlain, M C; Roth, P; Nemets, A; Shalom, E; Ben-Yehuda, D; Siegal, T (2010). Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. Blood, 115(24):5005-5011.

Wick, W; Puduvalli, V K; Chamberlain, M C; van den Bent, M J; Carpentier, A F; Cher, L M; Mason, W; Weller, M; Hong, S; Musib, L; Liepa, A M; Thornton, D E; Fine, H A (2010). Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. Journal of Clinical Oncology, 28(7):1168-1174.

Stupp, R; Hegi, M E; Mason, W P; van den Bent, M J; Taphoorn, M J B; Janzer, R C; Ludwin, S K; Allgeier, A; Fisher, B; Belanger, K; Hau, P; Brandes, A A; Gijtenbeek, J; Marosi, C; Vecht, C J; Mokhtari, K; Wesseling, P; Villa, S; Eisenhauer, E; Gorlia, T; Weller, M; Lacombe, D; Cairncross, J G; Mirimanoff, R O (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology, 10(5):459-466.

Gorlia, T; van den Bent, M J; Hegi, M E; Mirimanoff, R O; Weller, M; Cairncross, J G; Eisenhauer, E; Belanger, K; Brandes, A A; Allgeier, A; Lacombe, D; Stupp, R (2008). Nomograms for predicting survival of patients with newly diagnosed glioblastoma: Prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncology, 9(1):29-38.

This list was generated on Thu Jul 27 19:20:04 2017 CEST.